BioInvent International ABShs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.04.20	BioInvent Signs New Manufacturing Agreement With U.S. Cell Therapy Company (PR Newswire)
30.04.20	BioInvent Signs New Manufacturing Agreement With U.S. Cell Therapy Company (PR Newswire)
28.04.20	BioInvent Interim Report January 1 - March 31, 2020 (PR Newswire)
28.04.20	BioInvent Interim Report January 1 - March 31, 2020 (PR Newswire)
14.04.20	BioInvent Reports Promising Progress in Phase I/lla Trial of Lead Program BI-1206 in Combination with Rituximab (PR Newswire)
14.04.20	BioInvent Reports Promising Progress in Phase I/lla Trial of Lead Program BI-1206 in Combination with Rituximab (PR Newswire)
08.04.20	BioInvent: Annual Report 2019 (PR Newswire)
26.03.20	BioInvent Postpones the Annual General Meeting and Provides an Update on the Current Situation in Respect of COVID-19 (PR Newswire)
26.03.20	BioInvent Postpones the Annual General Meeting and Provides an Update on the Current Situation in Respect of COVID-19 (PR Newswire)
24.03.20	BioInvent and SkylineDx to Collaborate on Patient Stratification to Maximize Impact of Treatment with BI-1206 (PR Newswire)
24.03.20	BioInvent and SkylineDx to Collaborate on Patient Stratification to Maximize Impact of Treatment with BI-1206 (PR Newswire)
03.03.20	BioInvent and Transgene to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses (PR Newswire)
03.03.20	BioInvent and Transgene to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses (PR Newswire)
27.02.20	BioInvent Financial Statement January 1 - December 31, 2019 (PR Newswire)
27.02.20	BioInvent Financial Statement January 1 - December 31, 2019 (PR Newswire)
26.02.20	Ausblick: BioInvent International A legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
24.02.20	Invitation to Presentation of BioInvent's Fourth Quarter Report 2019 on February 27, 2020 (PR Newswire)
24.02.20	Invitation to Presentation of BioInvent's Fourth Quarter Report 2019 on February 27, 2020 (PR Newswire)
23.12.19	BioInvent Announces Selection of Second Target and Extension of the Research Collaboration and License Agreement With Pfizer Inc. (PR Newswire)
23.12.19	BioInvent Announces Selection of Second Target and Extension of the Research Collaboration and License Agreement With Pfizer Inc. (PR Newswire)
18.12.19	BioInvent Has Entered Into a Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1206 in Combination With KEYTRUDA® in Advanced Solid Tumors (PR Newswire)
18.12.19	BioInvent Has Entered Into a Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1206 in Combination With KEYTRUDA® in Advanced Solid Tumors (PR Newswire)
11.12.19	BioInvent and Transgene Announce Compelling Preclinical Data for BT-001 in Solid Tumors (PR Newswire)
11.12.19	BioInvent and Transgene Announce Compelling Preclinical Data for BT-001 in Solid Tumors (PR Newswire)
08.11.19	BioInvent to Present BI-1206 Preclinical Data in Mantle Cell lymphoma at ASH 2019 (PR Newswire)
08.11.19	BioInvent to Present BI-1206 Preclinical Data in Mantle Cell lymphoma at ASH 2019 (PR Newswire)
23.10.19	BioInvent Signs Manufacturing Agreement With Cancer Research UK Expected to Generate Approximately SEK 30 Million (~$3 Million) (PR Newswire)
23.10.19	BioInvent Signs Manufacturing Agreement With Cancer Research UK Expected to Generate Approximately SEK 30 Million (~$3 Million) (PR Newswire)
22.10.19	Ausblick: BioInvent International A stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
22.08.19	BioInvent: Interim Report January 1 - June 30, 2019 (PR Newswire)
22.08.19	BioInvent: Interim Report January 1 - June 30, 2019 (PR Newswire)
21.08.19	BioInvent Will Conduct Phase l/lla Trial With BI-1206 in Combination With Pembrolizumab (Keytruda) in Solid Tumors (PR Newswire)
21.08.19	BioInvent Will Conduct Phase l/lla Trial With BI-1206 in Combination With Pembrolizumab (Keytruda) in Solid Tumors (PR Newswire)
20.08.19	BioInvent's Partner Oxurion NV has Reported Topline Month 3 Results of Phase lla Study Evaluating THR-317 (anti-PLGF), in Combination With Ranibizumab, for DME (PR Newswire)
20.08.19	BioInvent's Partner Oxurion NV has Reported Topline Month 3 Results of Phase lla Study Evaluating THR-317 (anti-PLGF), in Combination With Ranibizumab, for DME (PR Newswire)
15.08.19	USPTO Intends to Grant BioInvent Patent Relating to BI-1206 (PR Newswire)
15.08.19	USPTO Intends to Grant BioInvent Patent Relating to BI-1206 (PR Newswire)
14.08.19	Invitation to Presentation of BioInvent's Interim Report Q2-2019 on August 22, 2019 (PR Newswire)
14.08.19	Invitation to Presentation of BioInvent's Interim Report Q2-2019 on August 22, 2019 (PR Newswire)
31.07.19	BioInvent Announces Selection of First Target Discovered by BioInvent's Proprietary F.I.R.S.TTM Technology Platform Under Collaboration With Pfizer Inc. (PR Newswire)
31.07.19	BioInvent Announces Selection of First Target Discovered by BioInvent's Proprietary F.I.R.S.TTM Technology Platform Under Collaboration With Pfizer Inc. (PR Newswire)
04.07.19	BioInvent Receives Milestone Payment Related to TAK-169 Investigational New Drug Application (PR Newswire)
04.07.19	BioInvent Receives Milestone Payment Related to TAK-169 Investigational New Drug Application (PR Newswire)
02.07.19	Bioinvent Receives Ind Approval For Phase I/iia Trial of Anti-fcγriib Antibody (PR Newswire)
02.07.19	Bioinvent Receives Ind Approval For Phase I/iia Trial of Anti-fcγriib Antibody (PR Newswire)
12.06.19	BioInvent Publishes First Clinical Data From BI-1206 Phase l/lla Trials (PR Newswire)
03.06.19	BioInvent Submits IND for Phase I/IIa Trial of Anti-FcγRIIB Antibody (PR Newswire)
03.06.19	BioInvent Submits IND for Phase I/IIa Trial of Anti-FcγRIIB Antibody (PR Newswire)
22.05.19	BioInvent Interim Report January 1 - March 31, 2019 (PR Newswire)
22.05.19	BioInvent Interim Report January 1 - March 31, 2019 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swisscom	527.00	2.33 %	K V
Holcim	95.34	1.21 %	K V
UBS Group	30.42	0.86 %	K V
Roche Hldg G	289.00	0.45 %	K V
Swiss Re	141.65	0.35 %	K V
Givaudan	3’850.00	-1.48 %	K V
Lonza Grp	603.80	-1.50 %	K V
Alcon	82.30	-1.53 %	K V
Geberit	508.00	-1.74 %	K V
Part Grp Hldg	1’386.00	-2.26 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu BioInvent International ABShs

Aktien Top/Flop

Meistgelesene Nachrichten